Recent work has identified distinct molecular subgroups of acute myeloid leukemia (AML) with implications for disease classification and prognosis. NPM1 is one of the most common recurrently mutated genes in AML. NPM1 mutations often co-occur with FLT3-ITDs and mutations in genes regulating DNA methylation, such as DNMT3A, TET2, and IDH1/2. It remains unclear whether these genetic alterations are associated with distinct immunophenotypic findings or affect prognosis. We identified 133 cases of NPM1-mutated AML and correlated sequencing data with immunophenotypic and clinical findings. Of 84 cases (63%) that lacked monocytic differentiation 
| I N TR ODU C TI ON
Acute myeloid leukemia (AML) arises from clonal expansions of hematopoietic precursor cells harboring genetic mutations and/or chromosomal alterations that drive the disease. In recent years, multiple studies have characterized distinct molecular subgroups of AML, 1,2 and the presence of certain disease-associated mutations is now being used to classify disease, dictate prognosis and, in some cases, guide therapy. One of the most common recurrent driver mutations in AML is mutation of the nucleophosmin gene (NPM1), which is seen in approximately 30% of cases. 1, 3, 4 AML with mutated NPM1 is now recognized as a distinct entity in the World Health Organization classification.
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NPM1 mutations most commonly occur in de novo AML and are associated with a normal karyotype. 3, 6 AML with mutated NPM1 is associated with a favorable prognosis; however, this favorable prognostic effect is lost in the context of concomitant FLT3-ITD mutations, which commonly co-occur with NPM1 mutations. [7] [8] [9] [10] In addition to FLT3-ITD mutations, which are seen in 40-50% of AML with mutated NPM1, 1,3,7,9,10 mutations in genes regulating DNA methylation, including DNMT3A, TET2, IDH1, and IDH2, are also commonly seen in the context of NPM1 mutations. 1 Multiple studies have shown that approximately 40-50% of NPM1-mutated AMLs harbor co-mutations in TET2
or IDH1/2. 1,11-14 TET2 and IDH1/2 mutations co-occur only very rarely and are thought to act in part through a common mechanism. IDH1/2 mutations are usually gain-of-function mutations that increase the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG inhibits the DNA demethylase function of TET2, thus leading to the same end result as TET2 loss-of-function mutations. 15, 16 While TET2 mutations appear to negatively affect prognosis in AML, 17 
| Statistical analysis
Fisher's exact tests and Mann-Whitney U tests were used to calculate statistical significance for categorical and continuous variables, respectively. Log-rank tests were used to analyze Kaplan-Meier curves, which were generated using Graphpad Prism 5.02 (www.graphpad.com). A P .05 was considered statistically significant.
| RE S U L TS
3.1 | A large subset of NPM1-mutated AML is negative for both CD34 and HLA-DR
Of the 133 cases of NPM1-mutated de novo AML identified, 49 (37%) cases showed morphologic, cytochemical, and/or immunophenotypic evidence of monocytic differentiation, while 84 (63%) cases lacked monocytic differentiation and were referred to as "myeloid AML".
Review of flow cytometric data demonstrated that 92 (69%) cases were negative for CD34, and 46 (36%) cases were negative for HLA-DR, a finding consistent with previously published reports. 3, 24, 27 Furthermore, 42 (32%) cases were negative for both CD34 and HLA-DR,
showing an acute promyelocytic leukemia-like (APL-like) phenotype (Supporting Information Figure 1 ). Because the vast majority of the APL-like cases belonged to the myeloid group (40/42; 95%), we focused our study on this specific subgroup of NPM1-mutated AML. Figure 1 ). Interestingly, the single case of NPM1-mutated myeloid AML with an APLlike phenotype that did not harbor a known pathologic variant in TET2 or IDH1/2 contained a variant of unknown significance in TET2 at an allele frequency of 97%, which suggests that, while definitive functional Therefore, the finding of an APL-like immunophenotype in an NPM1-mutated myeloid AML showed a sensitivity and specificity of identifying TET2 or IDH1/2 co-mutations of 70% and 96%, respectively. Thus, when present, this phenotype is highly specific for cases harboring TET2 or IDH1/2 co-mutations.
The finding that our APL-like cohort included cases harboring both TET2 and IDH1/2 co-mutations is perhaps not surprising, as TET2 and IDH1/2 mutations are thought to act in part through a common mechanism. TET2 is an alpha-ketoglutarate (a-KG)-dependent enzyme that is involved in the conversion of 5-methylcytosine to 5-hydroxymethylcytosine (5-hmc), which is required for subsequent DNA demethylation. 16 TET2 behaves like a tumor suppressor, with tumorassociated TET2 mutations causing loss of catalytic function. 35 IDH proteins normally convert isocitrate into a-KG; however, mutations in IDH1 and IDH2 lead to decreased production of a-KG, which is instead converted to the oncometabolite 2-hydroxyglutarate (2-HG). 36 2-HG shares structural similarities with a-KG and is thought to competitively inhibit the binding of a-KG to TET2, thus inhibiting TET2 function and leading to subsequent DNA hypermethylation. 15, 16 Interestingly, all IDH2 mutations seen in our cohort represented R140 mutations; no R172 mutations were identified, which is consistent with previous reports and suggests a distinct pathobiology associated with IDH2 R172 mutations. 1, 14, 37 Furthermore, we did not identify any WT1 mutations in our APLlike cohort. WT1 mutations are thought to be predominantly mutually exclusive of TET2 and IDH1/2 mutations, due at least in part to the fact that WT1 mutations appear to disrupt TET2 function. 33 Indeed, WT1
has been shown to directly bind to TET2, 34 and loss of WT1 has been shown to cause decreased 5-hmc production. 33 However, the lack of WT1 mutations in our APL-like cohort suggest that, at least in the context of NPM1 co-mutation, WT1 mutations act through additional pathways beyond TET2 dysregulation.
Our finding that NPM1-mutated myeloid AML with an APL-like phenotype correlates with a particular genetic signature is especially significant given the recent development of targeted inhibitors of mutant IDH1/2, which are currently under investigation in multiple clinical trials. 38 While molecular testing is increasingly being included in the work up of AML, the extent to which multigene panels, including TET2
and IDH1/2, are utilized varies depending on the institution. Notably, we found that our cohort of cases with an APL-like phenotype demonstrated a relatively low frequency of DNMT3A mutations, which may have contributed to the superior outcomes seen in this group. DNMT3A mutations are commonly associated with NPM1 mutations and have been shown to co-occur with IDH mutations as well. 1, 39, 40 Multiple studies have demonstrated an unfavorable effect of DNMT3A mutations on overall and relapse-free survival in AML patients. 40, 41 DNMT3A mutations were present at an overall frequency of 40% in our cohort of patients with NPM1-mutated AML, which is somewhat lower than what has been previously reported. 1, 13, 14 In our cohort of APL-like cases, which showed a more differentiated phenotype, the frequency of DNMT3A mutations was lower still, at 18%.
Interestingly, DNMT3A mutations are extremely uncommon in acute promyelocytic leukemia, 1, 42 suggesting either that the alterations in DNA methylation caused by DNMT3A mutations lead to maturation arrest at a more immature or stem cell stage or that DNMT3A mutations only rarely occur at later stages of myeloid differentiation.
In addition to identifying cases harboring TET2 or IDH1/2 comutations, the presence of an APL-like phenotype in cases of NPM1-mutated myeloid AML may also provide insight into disease biology. 45 In addition, recent work has also shown that ATRA treatment leads to terminal granulocytic differentiation in IDH1-mutant cell lines and primary patient samples, 46 which is thought to be related at least in part to the dysregulation of genes involved in retinoic acid response pathways seen in the context of IDH mutations. 46, 47 Together with these findings, our results suggest that there may be similarities in the biology underlying APL and NPM1-mutant myeloid AML with TET2 or IDH co-mutations, which could potentially be exploited in the development of future treatment strategies. Future studies are needed to fully elucidate the mechanisms that underlie these distinct molecular subgroups of AML and to understand how the presence of different mutations may affect prognosis and response to therapy.
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